About 1 500 reports

  • Interventional oncology market in EMEA
  • Interventional oncology market in Americas

About Interventional Oncology Interventional oncology procedures involve the diagnosis and treatment of cancer and cancer-related problems by using minimally invasive (MI) procedures performed under image guidance. Interventional oncology uses X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to...

  • Oncology
  • World
  • Boston Scientific Corporation
  • Medtronic, Inc.
  • Terumo Corporation
  • BIOLOGICS IN ONCOLOGY
  • APPROVED ONCOLOGY BIOSIMILARS

Biosimilars in Oncology Summary Recent trends in drug development have seen the price of new medicines continually increase, and there is a need for cheaper medicines to achieve global sustainable healthcare.Biologic drugs are some of the most expensive medicines to develop, as they are large complex...

  • Oncology
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • Oncology Drugs Market Segmentation
  • Oncology Drugs Market Characteristics

Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors. These drugs prevent the growth of malignant tumors by affecting the...

  • Oncology
  • World
  • Company Financials
  • Gilead Sciences, Inc.
  • Novartis AG

Chapter ## provides an introduction to the report.

  • Cancer
  • Oncology
  • Therapy
  • World
  • Demand

Oncology Drugs Global Market Report 2018 ##.

  • Cancer
  • Oncology
  • Pathology
  • World

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-##, PD-L##, CTLA-##]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022 ##.

  • Oncology
  • Therapy
  • World
  • Market Size

Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025 Table ## Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025 Table ## Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2015–2025 Tab

  • Biosimilar
  • Oncology
  • APAC
  • World
  • Market Size
  • Global oncology biosimilars segmentation by application
  • Oncology biosimilars market in China: SWOT analysis

About Oncology Biosimilars Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting....

  • Oncology
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Sandoz Inc.
  • ONCOLOGY, GLOBAL, PIPELINE FOR ONCOLOGY BY MOLECULAR TARGET, 2017
  • ONCOLOGY, GLOBAL, PIPELINE FOR KEY ONCOLOGY INDICATIONS BY STAGE OF DEVELOPMENT,

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors Summary Oncology comprises a large and diverse group of indications, encompassing virtually all sites and tissues in the human body. The diseases are characterized by abnormal cell proliferation,...

  • Oncology
  • World
  • Celgene Corporation
  • Novartis AG
  • Pfizer Inc.
  • Future Uses of PARP Inhibitors in Oncology
  • FUTURE USES OF PARP INHIBITORS IN ONCOLOGY

PARP Inhibitors in Oncology Summary Poly (ADP-ribose) polymerase (PARP) enzymes play important roles in the repair of single-strand breaks (SSBs) in DNA.SSBs occur from environmental agents, spontaneous DNA bond disruption, or normal DNA metabolism. PARP1 binds to DNA following SSB and recruits...

  • Oncology
  • Targeted Therapy
  • United States
  • AbbVie Inc.
  • Pfizer Inc.
  • 2 Supportive Care Oncology: Executive Summary
  • 3.4 EPIDEMIOLOGICAL FORECAST FOR SUPPORTIVE CARE IN ONCOLOGY (2016-2026)

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026 Summary Cancer is a broad term for a group of diseases characterized by uncontrolled cell proliferation in any part of the body that may spread beyond the cells’ normal boundaries (WHO, 2017). Worldwide, it is estimated that...

  • Blood Disease
  • Oncology
  • United States
  • World
  • Forecast

Generic Oncology Drug Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023 ## Preface ## Scope and Methodology ##. ## Objectives of the study ##. ## Stakeholders ##. ## Data Sources ##. ##. ## Primary Sources ##. ##. ## Secondary Sources ##. ## Market Estimation ##. ##. ## Bo

  • Generic Drug
  • Oncology
  • Therapy
  • World
  • Market Size

##.

  • Oncology
  • Therapy
  • World
  • Market Size
  • Immuno-oncology
  • Patient Access to Oncology Medicines

Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU Summary Market access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more stringent scientific and value assessments and economic pressures on national budgets and...

  • Oncology
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • PROVENGE group
  • SUPPORTIVE ONCOLOGY
  • 4.6.2 CURRENT STATE OF SUPPORTIVE ONCOLOGY IN JAPAN

PharmaFocus: Supportive Care in Oncology Summary Supportive care in oncology is a broad term that is composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced...

  • Oncology
  • United States
  • Amgen Inc.
  • BeyondSpring Pharmaceuticals Inc.
  • Helsinn Group

PD-## ##. ##. ##. ##.

  • Oncology
  • Therapy
  • World
  • Market Size
  • JNJ
  • 11 Aug 2014

CDT during the " Plenary Session: Including the Science of Oncology Award and Lecture" at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

  • Oncology
  • United States
  • Demand
  • Genmab group
  • Janssen Biotech, Inc.
  • BASIC INFORMATION

Kadcyla | ado-trastuzumab Oncology drug report: 2013-2015 analysis, 2016-2021 expectations emtansine December 2016 Armed antibody Kadcyla | ado-trastuzumab emtansine 2013-2015 analysis; 2016-2021 expectations Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Chemotherapy
  • Oncology
  • Therapy
  • North America
  • United States

Baynes, MD, PhD, Senior Vice President, Oncology and Inflammation Therapeutics at Gilead.

  • Leukemia
  • Oncology
  • United States
  • Gilead Sciences, Inc.
  • Roche Group
  • ONGOING TRIALS OF PERJETA
  • DDAC=DOSE-DENSE DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; FEC = FLUOROURACIL, EPIRUBICIN, AND CYCLOPHOSPHAMIDE

Perjeta|pertuzumab Oncology drug report: 2012-2015 analysis, 2016-2021 expectations December 2016 In the spotlight Perjeta | pertuzumab 2012-2015 analysis; 2016-2021 expectations Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Oncology
  • North America
  • United States
  • Demand
  • Roche Group

Iressa | gefitinib Oncology drug report: 2002-2015 analysis, 2016-2021 expectations December 2016 Iressa | gefitinib 2006-2015 analysis; 2016-2021 expectations On a downward spiral Oncology Drug Report ANALYST Cancer Therapy Research Team Vikas.

  • Oncology
  • United States
  • Demand
  • AstraZeneca PLC
  • Roche Group

This unique product is truly the only one of its kind and is designed to give you a competitive edge in your bispecific drug intelligence.

  • Oncology
  • Therapy
  • NEWS AROUND BLINCYTO
  • 01 Sept 16

Stein, M. D., clinical professor, Hematology/ Oncology at City of Hope.

  • Oncology
  • Therapy
  • United States
  • Demand
  • Amgen Inc.
  • Ariad announces final decision from European Commission endorsing Iclusig's approved indications through-
  • BASIC INFORMATION

Iclusig|ponatinib Oncology drug report: 2013-2015 analysis, 2016-2021 expectations December 2016 Iclusig | ponatinib 2013-2015 analysis; 2016-2021 expectations Caught up in controversies Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Oncology
  • North America
  • United States
  • ARIAD Pharmaceuticals, Inc.
  • Incyte Corporation
  • 2 Sep 2013
  • NEWS AROUND HERCEPTIN

Oncology drug report: Her ceptin |tr astuzum ab 2006-2015 analysis, 2016-2021 expectations November 2016 Herceptin | trastuzumab 2006-2015 analysis; 2016-2021 expectations Steady decline seen ahead Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Oncology
  • North America
  • United States
  • Biocon Limited
  • Roche Group
  • Historical cumulative sales (2002 to 2015)
  • Till Q3- 2016

TS-## (tegafur, gimeracil, oteracil) ##.

  • Oncology
  • United States
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Neupogen group
  • Takeda announces the new drug application approval of Adcetris (brentuximab vedotin) in Japan for the treatment of malignant lymphoma
  • SALES MIX - US AND CANADA/INTERNATIONAL

Oncology drug report: Adcet ris |brentu xima b ved oti n 2011-2015 analysis, 2016-2021 expectations November 2016 Adcetris| brentuximab vedotin 2011-2015 analysis; 2016-2021 expectations Orphan drug growing steadily Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Oncology
  • North America
  • United States
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Royalty-related information
  • COMPANY PRESS RELEASES RELATED TO XALKORI

It is one of the major contributors to oncology revenue of Pfizer in recent years and is the third-largest oncology drug for the company.

  • Oncology
  • United States
  • AstraZeneca PLC
  • Pfizer Inc.
  • Roche Group
  • BASIC INFORMATION

NATIONAL ONCOLOGY COOPERATIVE GROUP.

  • Oncology
  • Targeted Therapy
  • United States
  • Demand
  • Celgene Corporation
  • CURRENT AND FUTURE DIRECTIONS IN THE ONCOLOGY BIOSIMILAR SPACE
  • BIOSIMILARS ARE SET TO CHANGE THE ONCOLOGY TREATMENT LANDSCAPE WITH THE APPROVALS OF COPYCAT VERSIONS OF MABS FOR CANCER TREATMENT.

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area Summary GlobalData’s "The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area", provides an insight-rich overview of the key events and trends that shaped the industry during 2017. Within each of the major therapeutic...

  • Oncology
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.